ADA recommends screening for nonalcoholic fatty liver disease in all diabetes patients.

The American Diabetes Association recommends that all adults with type 2 diabetes or prediabetes should be screened for nonalcoholic fatty liver disease, which can lead to serious liver damage. GLP-1 treatments, such as Ozempic and Mounjaro, are singled out as an option doctors could consider, as they have been shown to lower blood sugar and cut weight. However, there are no approved medications for the disease, and there is still limited data on the efficacy of GLP-1s in fatty liver disease.